Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Belite Bio, Inc. ADR ( (BLTE) ) just unveiled an update.
On August 11, 2025, Belite Bio announced its second quarter financial results and provided a corporate update, highlighting significant progress in its clinical programs. The company achieved a major milestone with the completion of enrollment in the Phase 3 PHOENIX trial for geographic atrophy and received Breakthrough Therapy Designation from the FDA for Tinlarebant in treating Stargardt disease. Additionally, Belite Bio raised approximately $15 million through a direct offering and reported increased research and development expenses, reflecting its ongoing commitment to advancing its clinical trials. The financial results showed a net loss of $16.3 million for the quarter, attributed to higher R&D and administrative expenses.
The most recent analyst rating on (BLTE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Belite Bio faces significant financial challenges with no revenue and increasing losses, impacting its overall score. Technical indicators show neutral momentum, and valuation is unattractive with negative earnings. However, the earnings call highlights clinical advancements and financial stability, providing a positive outlook in the long term despite current financial difficulties.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio is a clinical-stage drug development company based in San Diego, focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD). Their lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently undergoing Phase 3 and Phase 2/3 clinical trials.
Average Trading Volume: 48,995
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.27B
For detailed information about BLTE stock, go to TipRanks’ Stock Analysis page.